Navigation Links
Multiple Independent Studies Report on Use of Cylex's Immune Cell Function Assay in Postoperative Monitoring of Kidney, Liver, and Heart Transplant Recipients
Date:5/30/2008

Thirteen different studies, which included the use of ImmuKnow(R) to assess immune cell function, will be presented at the annual American Transplant

Congress

COLUMBIA, Md., May 30 /PRNewswire/ -- On Saturday, May 31 through Tuesday, June 3, at the annual American Transplant Congress (ATC) in Toronto, Canada, a total of 13 presentations will either report specifically on studies of the use of the ImmuKnow assay or will include information on the use of this assay in monitoring kidney, liver, and heart transplant patients over time.

Since it was initially cleared as an in vitro diagnostic technique to detect cell-mediated immunity (CMI) in adult patient populations undergoing immunosuppressive therapy for organ transplantation, understanding of the possible applications of the Cylex(TM) ImmuKnow assay (in clinical practice and in the clinical research setting) has continued to expand. Selected institutions are expected to issue their own detailed media information about individual studies (highlighted in bold type below). However, the full list of studies that is known to either focus on or include explicit reference to use of the ImmuKnow assay for CMI is as follows:

Saturday, May 31, 2008

-- "Is infection in heart transplant patients related to low immune cell

function or low white blood cell count or both?" (B. Pavlovic

Surjancev, P. Lingam, N. Patel, et al.) -- poster presentation, 5:30

p.m. - 7:00 p.m. (Poster Session: Heart Transplantation I)

This study, from Loyola University Medical Center in Maywood, IL,

assesses relative values of cell-mediated immunity, white blood cell

count, and lymphocyte count in monitoring 26 heart transplant patients

of whom 15 had various infections.

-- "Sirolimus (SRL) blunts mitogen response at trough (C0) levels more

than cyclosporine (CSA) or tacrolimus (TAC) -- a safeguard for our many

long-term noncompliant kidney transplant patients (KTPs)" (X. Ye, N.

Khosla, R. Batarse, et al.)

-- -- poster presentation, 5:30 p.m. -- 7:00 p.m. (Poster Session:

Psychosocial and Compliance Issues)

Mitogen response to three different immunosuppressive agents was

assessed in 160 kidney transplant patients at an average of more than 6

years post-surgery using the Cylex ImmuKnow assay in this study from

the University of California San Diego School of Medicine, San Diego,

CA.

-- "Anti-CD20 monoclonal antibody (Rituximab) clears persistent post

transplant (TX) EBV viremia, but the effect may not be sustained" (L.

Jinadu, M. Toyoda, E. Kamil, et al.) -- poster presentation, 5:30 p.m.

-- 7:00 p.m. (Poster Session: Kidney: Pediatrics)

This study, from Cedars Sinai Medical Center in Los Angeles, CA,

includes reference to the use of ImmuKnow in serial monitoring of 5

pediatric renal transplant patients being treated for persistent

Epstein-Barr viremia.

Sunday, June 1, 2008

-- "Effect of induction agent on cellular and humoral responses to renal

transplants in sensitized patients" (M. S. Leffell, D. Kopchliiska, D.

P. Lucas, et al.) -- oral presentation, 3:35 p.m. (Concurrent Session:

Immunosuppression: Protocols for Sensitized and ABO Incompatible Renal

Transplantation: A Period of Consolidation)

CMI was one of three parameters assayed in monitoring the

responses of renal transplant patients to two different induction

agents in this study from Johns Hopkins University School of Medicine,

Baltimore, MD.

-- "411 living donor kidney transplants using alemtuzumab pre-conditioning

and tacrolismus monotherapy: 5-year experience" (H. P. Tan, J.

Donaldson, A. Basu, et al.) -- oral presentation, 4:20 p.m. (Concurrent

Session: Kidney Immunosuppression: Induction Therapy I)

This study from the University of Pittsburgh Medical Center

reports the 5-year results of the largest series (to date) of living

kidney donor transplants with alemtuzumab preconditioning, including

the role of the Cylex ImmuKnow assay in patient monitoring to assist in

the weaning of recipients to tacrolimus monotherapy.

-- "Monitoring of immune function for treatment of post-transplant de novo

malignancy" (T. Uemura, T. R. Riley III, A. Khan, et al.) -- poster

presentation, 5:00 p.m. -- 6:00 p.m. (Poster Session:

PTLD/Malignancies: All Topics)

The Cylex ImmuKnow assay was used to compare outcomes of 52 kidney

and liver transplant patients with de novo malignancies post transplant

in this study from the Penn State Milton S. Hershey Medical Center,

Hershey, PA.

-- "New insights into the use of immune cell function monitoring in kidney

transplant management" (F. Benitez, A. Gautam, and N. Najafian) --

poster presentation, 5:00 p.m. -- 6:00 p.m. (Poster Session: Non

Invasive Immune Monitoring II)

This pilot study from the Children's Hospital, Brigham and Women's

Hospital, and Boston Medical Center, Boston, MA suggests three new

findings related to the use of CMI in post-transplant monitoring of

patients with kidney transplants.

Monday, June 2, 2008

-- "Rejection characteristics of 200 living donor kidney transplants using

alemtuzumab induction and tacrolismus monotherapy" (H. P. Tan, J.

Donaldson, A Basu, et al.) -- oral presentation, 2:15 p.m. (Concurrent

Session: Kidney -- Acute Rejection: Immunosuppressive Agents and

Registry Data)

This study from the University of Pittsburgh Medical Center

reports the longest (3-year) follow-up of the largest series (to date)

of living kidney donor transplants with alemtuzumab preconditioning

and tacrolimus monotherapy, including the role of the Cylex ImmuKnow

assay in patient monitoring.

-- "Relationship between immune function and humoral sensitization in

renal transplant recipients" (A. Zeevi, C. Bentlejewski, A. Girnita et

al.) -- poster presentation, 5:00 p.m. -- 6:00 p.m. (Poster Session:

Kidney Immunosuppression: Induction Therapy)

This study of 290 samples from 39 renal transplant recipients from

the University of Pittsburgh Medical Center and Cylex, Inc. suggests

that cell-mediated immune function and anti-HLA antibody screening

tests are independent measures of different arms of the immune

response.

-- "ATP levels (ATP) analyzed by Cylex ImmuKnow assay (ICF) are useful to

guide management of CMV and BKV infection, but has limited utility for

EBV" (D. Thomas, A. Pao, D. Puliyanda, et al.) -- poster presentation,

5:00 p.m. -- 6:00 p.m. (Poster Session: Kidney: Complications IV)

The role of CMI in guiding the management of CMV and BKV

infections in 194 kidney transplant patients over a period of 3 years

is clarified in this study from the Cedars Sinai Medical Center, Los

Angeles, CA.

-- "Immune monitoring with Cylex ImmuKnow in the management of post kidney

transplant recipients" (M. R. Carreno, T. Cordovilla, Y Jin, et al.) --

poster presentation, 5:00 p.m. -- 6:00 p.m. (Poster Session: Kidney:

Complications IV)

The role of CMI in guiding the post-transplantation management of

339 kidney transplant patients is examined in this study of over 2,000

test specimens from the University of Miami Lawrence Miller School of

Medicine, Miami, FL.

-- "The ATP release assay in normal, dialysis and transplant patients, and

its practical application" (E. A. Santiago-Delpin, S. de Echegaray, D.

M. Perez, et al.) -- poster presentation, 5:00 p.m. -- 6:00 p.m.

(Poster Session: Kidney: Complications IV)

This case-control approach to measuring CMI involved monitoring

Hispanic kidney transplant patients together with CMI values in normal

Hispanics and Hispanic patients on dialysis in this study from the

University of Puerto Rico, San Juan, PR.

Tuesday, June 3, 2008

-- "Impact of Cylex immune cell function assay in predicting acute

cellular rejection and recurrence of HCV in liver transplantation" (K.

Hashimoto, K. Hirose, T. Diago Uso, et al.) -- poster presentation,

5:00 p.m. -- 6:00 p.m. (Poster Session: Liver: Hepatitis)

The role of CMI in monitoring 63 patients receiving orthotopic

liver transplants, with a specific focus on the ability to distinguish

acute cellular rejection from HCV recurrence, is examined in this study

from The Cleveland Clinic, Cleveland, OH.

The various studies report on the clinical use of the ImmuKnow immune function assay in adult and in pediatric patients. The use of the ImmuKnow assay for identification of patients at risk for organ rejection and/or infection, as described in some of these studies, has not been cleared by the U.S. Food & Drug Administration (FDA). The company may use data from these or similar studies to support future FDA marketing applications.

About ImmuKnow(R)

ImmuKnow is an immune cell function assay that can detect cell-mediated immunity in adult patient populations undergoing immunosuppressive therapy for organ transplantation by measuring the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation.

The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of ImmuKnow assays should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient. The ImmuKnow assay has not been cleared by FDA for assessment of immune cell function in pediatric patients.

About Cylex, Incorporated

Cylex(TM) is a privately held global life sciences company and a leader in the development and manufacture of research and in vitro diagnostic products intended to assist in the assessment of immune function. Cylex is the first and only company to offer a patent-protected in vitro diagnostic assay (ImmuKnow) used in the detection of cell-mediated immune function in immune-suppressed organ transplant patient populations. The ImmuKnow assay is increasingly being adopted for use by organ transplant centers throughout the USA and in other countries around the world.

The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure immune cell function for the development of new diagnostics, biomarkers, and companion assays. The company is based in Columbia, MD.

CONTACT: Lynn Shepherd Ketura Lispi

Vox Medica Vox Medica

(267) 250-7376 (215) 925-9901

lshepherd@voxmedica.com klispi@voxmedica.com


'/>"/>
SOURCE Cylex, Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. New MRI finding sheds light on multiple sclerosis disease progressio
3. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
4. Emory researchers identify signaling protein for multiple myeloma
5. Study suggests brain tumors need treatment with multiple targeted drugs
6. Gene profiling can single out the worst cases of multiple myeloma and guide therapy
7. Cell-surface sugar defects may trigger nerve damage in multiple sclerosis patients
8. Multiple corticosteroid injections in pregnant women may increase cerebral palsy
9. Multiple Sclerosis Patients Find Dietary Treatment More Effective Than Pharmaceutical Regimens
10. IVF technique enables pregnancy without multiple births, Stanford researchers find
11. Ingenious Med Forms Multiple Billing Company Partnerships to Market Inpatient Practice Management Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology: